Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data.
暂无分享,去创建一个
T Ishizaki | K Chiba | Y. Sugiyama | C. Tyson | K. Chiba | T. Ishizaki | C. Green | H. Suzuki | T Iwatsubo | N Hirota | T Ooie | H Suzuki | N Shimada | C E Green | C A Tyson | Y Sugiyama | T. Iwatsubo | T. Ooie | N. Shimada | N. Hirota | Hiroshi Suzuki | Noriaki Shimada | Kan Chiba | Takashi Ishizaki | Yuichi Sugiyama | Carol E. Green | Charles A. Tyson
[1] G. de Sousa,et al. Interspecies variability in mitoxantrone metabolism using primary cultures of hepatocytes isolated from rat, rabbit and humans. , 1991, Biochemical pharmacology.
[2] G L Amidon,et al. The influence of the interdigestive migrating myoelectric complex on the gastric emptying of liquids. , 1990, Gastroenterology.
[3] M. Gibaldi,et al. The warfarin‐sulfinpyrazone interaction: stereochemical considerations , 1986, Clinical pharmacology and therapeutics.
[4] J. Cannon,et al. Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine (ARA-C) deamination in several species. , 1973, Biochemical pharmacology.
[5] J. Lin,et al. Kinetic studies on the deethylation of ethoxybenzamide. A comparative study with isolated hepatocytes and liver microsomes of rat. , 1980, Biochemical pharmacology.
[6] D. Greenblatt,et al. Alprazolam metabolism in vitro: studies of human, monkey, mouse, and rat liver microsomes. , 1993, Pharmacology.
[7] J. Caldwell,et al. A metabolic and pharmacokinetic comparison of theophylline and aminophylline (theophylline ethylenediamine) , 1981, The Journal of pharmacy and pharmacology.
[8] G R Wilkinson,et al. Clearance approaches in pharmacology. , 1987, Pharmacological reviews.
[9] J. Lin,et al. Species similarities and differences in pharmacokinetics. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[10] R. Chenery,et al. Comparative drug metabolism of diazepam in hepatocytes isolated from man, rat, monkey and dog. , 1989, Biochemical pharmacology.
[11] B. Dvorchik,et al. Studies on the disposition of antipyrine, aminopyrine, and phenacetin using plasma, saliva, and urine , 1975, Clinical pharmacology and therapeutics.
[12] M. Gibaldi,et al. Characteristics of warfarin hydroxylation catalyzed by human liver microsomes. , 1989, Drug metabolism and disposition: the biological fate of chemicals.
[13] W. L. Nelson,et al. Inhibition of the enantioselective oxidative metabolism of metoprolol by verapamil in human liver microsomes. , 1993, Drug metabolism and disposition: the biological fate of chemicals.
[14] P. Beaune,et al. Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. , 1991, Biochemical pharmacology.
[15] P. Meffin,et al. Influence of acute viral hepatitis on disposition and plasma binding of tolbutamide , 1977, Clinical pharmacology and therapeutics.
[16] T. Shimada,et al. Lidocaine metabolism by human cytochrome P-450s purified from hepatic microsomes: comparison of those with rat hepatic cytochrome P-450s. , 1990, The Journal of pharmacology and experimental therapeutics.
[17] K. Bischoff,et al. Methotrexate pharmacokinetics. , 1971, Journal of pharmaceutical sciences.
[18] R. Elofsson,et al. Binding of two adrenergic beta-receptor antagonists, alprenolol and H 93-26, to human serum proteins. , 1974, Acta pharmaceutica Suecica.
[19] P. Robinson,et al. Hepatic elimination of flowing substrates: the distributed model. , 1978, Journal of theoretical biology.
[20] L. Bass,et al. Physiologically based models and strategic experiments in hepatic pharmacology. , 1988, Biochemical pharmacology.
[21] J. Miners,et al. Lidocaine disposition—Sex differences and effects of cimetidine , 1984, Clinical pharmacology and therapeutics.
[22] M. Eichelbaum,et al. Physiological disposition of verapamil in man. , 1976, Cardiovascular research.
[23] M. Bayliss,et al. Prediction of intrinsic clearance of loxtidine from kinetic studies in rat, dog and human hepatocytes. , 1990, Biochemical Society transactions.
[24] R. Ogilvie,et al. Pharmacokinetics of intravenous theophylline , 1973, Clinical pharmacology and therapeutics.
[25] M. Rowland,et al. Models of hepatic drug clearance: discrimination between the ‘well stirred’ and ‘parallel‐tube’ models , 1983, The Journal of pharmacy and pharmacology.
[26] M. Eichelbaum,et al. Stereoselective protein binding of verapamil enantiomers. , 1988, Biochemical pharmacology.
[27] M. Eichelbaum,et al. Predictability of the in vivo metabolism of verapamil from in vitro data: contribution of individual metabolic pathways and stereoselective aspects. , 1992, The Journal of pharmacology and experimental therapeutics.
[28] J. Timbrell,et al. Factors affecting the metabolism of phenacetin. I. Influence of dose, chronic dosage, route of administration and species on the metabolism of (1-14C-acetyl)phenacetin. , 1974, Xenobiotica; the fate of foreign compounds in biological systems.
[29] Y. Sugiyama,et al. Applications and prospects for physiologically based pharmacokinetic (PB-PK) models involving pharmaceutical agents. , 1995, Toxicology letters.
[30] M. Rowland,et al. Correlation between in‐vitro microsomal enzyme activity and whole organ hepatic elimination kinetics: analysis with a dispersion model , 1986, The Journal of pharmacy and pharmacology.
[31] L. Benet,et al. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction , 1992, Clinical pharmacology and therapeutics.
[32] J. Clements,et al. Absorption, distribution and elimination of mexiletine. , 1977, Postgraduate medical journal.
[33] T. Ishizaki,et al. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese , 1989, Clinical pharmacology and therapeutics.
[34] T Iwatsubo,et al. PREDICTION OF IN VIVO DRUG DISPOSITION FROM IN VITRO DATA BASED ON PHYSIOLOGICAL PHARMACOKINETICS , 1996, Biopharmaceutics & drug disposition.
[35] R. Ogilvie,et al. Theophylline disposition in patients with hepatic cirrhosis. , 1977, The New England journal of medicine.
[36] R. Kato,et al. Cytochrome P450 mediated metabolism of diazepam in human and rat: involvement of human CYP2C in N-demethylation in the substrate concentration-dependent manner. , 1993, Pharmacogenetics.
[37] J B Houston,et al. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. , 1994, Biochemical pharmacology.
[38] H. Yamazaki,et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.
[39] J. Turgeon,et al. Erythrocyte and serum distribution of mexiletine in man. , 1987, Biopharmaceutics & drug disposition.
[40] B. Hoener,et al. Predicting the hepatic clearance of xenobiotics in humans from in vitro data , 1994, Biopharmaceutics & drug disposition.
[41] R. Kato,et al. The importance of substrate concentration in determining cytochromes P450 therapeutically relevant in vivo. , 1994, Pharmacogenetics.
[42] W. Trager,et al. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. , 1994, The Journal of pharmacology and experimental therapeutics.
[43] K. Chiba,et al. The role of S-mephenytoin 4'-hydroxylase in imipramine metabolism by human liver microsomes: a two-enzyme kinetic analysis of N-demethylation and 2-hydroxylation. , 1994, British journal of clinical pharmacology.
[44] P. Beaune,et al. Expression of human liver cytochrome P450 IIIA4 in yeast. A functional model for the hepatic enzyme. , 1990, European journal of biochemistry.
[45] J. Miners,et al. Characterisation of theophylline metabolism in human liver microsomes. , 1987, British journal of clinical pharmacology.
[46] K H Antonin,et al. Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat. , 1976, The Journal of pharmacology and experimental therapeutics.
[47] D. Smith,et al. Pharmacokinetics and metabolism of dofetilide in mouse, rat, dog and man. , 1992, Xenobiotica; the fate of foreign compounds in biological systems.
[48] D. Ciraulo,et al. Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers , 1988, Clinical pharmacology and therapeutics.
[49] S. Otton,et al. In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver. , 1988, Drug metabolism and disposition: the biological fate of chemicals.
[50] Beckett Ah,et al. The distribution, metabolism and excretion of mexiletine in man. , 1977 .
[51] T. Suzuki,et al. Drug absorption and metabolism studies by use of portal vein infusion in the rat. II. Influence of dose and infusion rate on the bioavailability of propranolol. , 1974, Chemical & pharmaceutical bulletin.
[52] M. Kendall,et al. The effect of age on the pharmacokinetics of metoprolol and its metabolites. , 1981, British journal of clinical pharmacology.
[53] M. Grant,et al. Human adult hepatocytes in primary monolayer culture. Maintenance of mixed function oxidase and conjugation pathways of drug metabolism. , 1987, Biochemical pharmacology.
[54] C. Libersa,et al. Mexiletine metabolism in vitro by human liver. , 1990, Drug metabolism and disposition: the biological fate of chemicals.
[55] R. Boyes,et al. The tissue distribution, metabolism and excretion of lidocaine in rats, guinea pigs, dogs and man. , 1972, The Journal of pharmacology and experimental therapeutics.
[56] G R Wilkinson,et al. Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. , 1977, The Journal of pharmacology and experimental therapeutics.
[57] J. Lin,et al. Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[58] Grant R. Wilkinson,et al. A physiological approach to hepatic drug clearance , 1975 .
[59] U. Meyer,et al. Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4 , 1989, Clinical pharmacology and therapeutics.